Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin. Issue 1 (October 2015)

• Record Type: Journal Article
• Authors: D'Amico, Fabio; Trovato, Chiara; Skarmoutsou, Evangelia; Rossi, Giulio A.; Granata, Mariagrazia; Longo, Valentina; Gangemi, Pietro; Pettinato, Maurizio; Mazzarino, Maria Clorinda
• Is Part Of: Journal of dermatological science. Volume 80:Issue 1(2015:Oct.)
• Page Start: 38
• Page End: 44
• Publication Date: 2015-10
• Subjects: S100A7 -- Psoriasin -- Psoriasis -- Biological therapy -- TNF -- IL-12/-23p40; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2015.07.009
• Languages: English
• ISSNs: 0923-1811

Abstract

Highlights: S100A7 production is increased under inflammatory contexts, such as in psoriasis. Adalimumab, etanercept or ustekinumab downregulate S100A7 to a different extent. Limiting the action of S100A7 may represent a therapeutic approach for psoriasis. Abstract: Background: Psoriasis is a chronic inflammatory skin disease. It is characterized by immune cell activation and altered epidermal differentiation. S100A7 (psoriasin) is overexpressed in psoriasis, suggesting a determinant role of this protein in inflammation and keratinocyte differentiation. Objective: The purpose of this study was to investigate the expression of S100A7 in the skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab. Methods: S100A7 expression and distribution were analyzed by immunohistochemistry. Results: S100A7, overexpressed in epidermal keratinocytes of psoriatic lesions, was downregulated, under the biological therapy with adalimumab, etanercept or ustekinumab, only in patients achieving a PASI score < 15. Conclusions: Dysregulation of S100A7 may represent a non-negligible player in the maintenance of psoriasis and the relative epidermal changes. Blockage of S100A7 may represent an additional therapeutic approach in the treatment of psoriasis.